Assessing How Consumers Interpret and Act on Results From At-Home COVID-19 Self-test Kits A Randomized Clinical Trial

被引:21
|
作者
Woloshin, Steven [1 ,2 ]
Dewitt, Barry [3 ,4 ]
Krishnamurti, Tamar [5 ]
Fischhoff, Baruch [3 ]
机构
[1] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med Media, Lebanon, NH 03756 USA
[2] Lisa Schwartz Fdn Truth Med, Norwich, VT USA
[3] Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA
[4] Lund Univ, Dept Clin Sci, Med Eth, Lund, Scania, Sweden
[5] Univ Pittsburgh, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA
基金
美国医疗保健研究与质量局;
关键词
D O I
10.1001/jamainternmed.2021.8075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The US Food and Drug Administration (FDA) authorized SARS-CoV-2 rapid at-home self-test kits for individuals with and without symptoms. How appropriately users interpret and act on the results of at-home COVID-19 self-tests is unknown. OBJECTIVE To assess how users of at-home COVID-19 self-test kits interpret and act on results when given instructions authorized by the FDA, instructions based on decision science principles, or no instructions. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted of 360 adults in the US who were recruited in April 2021 to complete an online survey on their interpretation of at-home COVID-19 self-test results. Participants were given 1 of 3 instruction types and were presented with 1 of 4 risk scenarios. Participants were paid $5 and had a median survey completion time of 8.7 minutes. Data analyses were performed from June to July 2021. INTERVENTION Participants were randomized to receiving either the FDA-authorized instructions (authorized), the intervention instructions (intervention), or no instructions (control), and to 1 of 4 scenarios: 3 with a high pretest probability of infection (COVID-19 symptoms and/or a close contact with COVID-19) and 1 with low pretest probability (no symptoms and no contact). The intervention instructions were designed using decision science principles. MAIN OUTCOMES AND MEASURES Proportion of participants in the high pretest probability scenarios choosing to quarantine per federal recommendations and perceived probabilities of infection given a negative or positive COVID-19 test result. A Bonferroni correction accounted for multiple comparisons (3 instruction types x 4 scenarios; alpha = 0.004). RESULTS After excluding 22 individuals who completed the survey too quickly, the responses of 338 participants (median [IQR] age, 38 [31 to 48] years; 154 (46%) women; 215 (64%) with a college degree or higher) were included in the study analysis. Given a positive test result, 95%(322 of 338; 95% CI, 0.92 to 0.97) of the total participants appropriately chose to quarantine regardless of which instructions they had received. Given a negative test result, participants in the high pretest probability scenarios were more likely to fail to quarantine appropriately with the authorized instructions (33%) than with the intervention (14%; 95% CI for the 19% difference, 6% to 31%; P =.004) or control (24%; 95% CI for the 9% difference, -4% to 23%; P =.02). In the low pretest probability scenario, the proportion choosing unnecessary quarantine was higher with the authorized instructions (31%) than with the intervention (22%; 95% CI for the 9% difference, -14% to 31%) or control (10%; 95% CI for the 21% difference, 0.5% to 41%)-neither comparison was statistically significant (P =.05 and P =.20 respectively). CONCLUSIONS AND RELEVANCE The findings of this randomized clinical trial indicate that at-home COVID-19 self-test kit users relying on the authorized instructions may not follow the Centers for Disease Control and Prevention's quarantine recommendations, producing unintended risks and unnecessary disruptions. Redesigned instructions that follow decision science principles may improve compliance.
引用
收藏
页码:332 / 341
页数:10
相关论文
共 50 条
  • [41] Heart Failure Clinical Trial Operations During the COVID-19 Pandemic Results From a Multicenter Survey
    Samsky, Marc D.
    DeVore, Adam D.
    McIlvennan, Colleen K.
    Granger, Christopher B.
    Granger, Bradi B.
    Hernandez, Adrian F.
    Felker, G. Michael
    Fonarow, Gregg C.
    Albert, Nancy M.
    Pina, Ileana L.
    Lanfear, David
    Allen, Larry A.
    CIRCULATION-HEART FAILURE, 2020, 13 (09) : E007456
  • [42] Late versus early administration of convalescent plasma in hospitalized patients with COVID-19: Results from the randomized open label clinical trial CAPSID
    Koerper, S.
    Weiss, M.
    Zickler, D.
    Wiesmann, T.
    Zacharowski, K.
    Corman, V. M.
    Gruener, B.
    Ernst, L.
    Spieth, P.
    Lepper, P. M.
    Bentz, M.
    Zinn, S.
    Paul, G.
    Kalbhenn, J.
    Dollinger, M.
    Rosenberger, P.
    Kirschning, T.
    Thiele, T.
    Appl, T.
    Mayer, B.
    Schmidt, M.
    Drosten, C.
    Wulf, H.
    Kruse, J. M.
    Jungwirth, B.
    Seifried, E.
    Schrezenmeier, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 118 - 118
  • [43] Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study
    Shepshelovich, Daniel
    Yahav, Dafna
    Ben Ami, Ronen
    Goldvaser, Hadar
    Tau, Noam
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (09) : 2415 - 2418
  • [44] Effect of a Virtual Home-Based Behavioral Intervention on Family Health and Resilience During the COVID-19 Pandemic: A Randomized Clinical Trial
    Popescu, Filoteia
    Sommer, Evan C.
    Mahoney, Margaret R.
    Adams, Laura E.
    Barkin, Shari L.
    JAMA NETWORK OPEN, 2022, 5 (12) : e2247691
  • [45] Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
    Di Pierro, Francesco
    Iqtadar, Somia
    Khan, Amjad
    Mumtaz, Sami Ullah
    Chaudhry, Mohsin Masud
    Bertuccioli, Alexander
    Derosa, Giuseppe
    Maffioli, Pamela
    Togni, Stefano
    Riva, Antonella
    Allegrini, Pietro
    Khan, Saeed
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 2807 - 2816
  • [46] Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial
    Joseph Miller
    Charles Bruen
    Michael Schnaus
    Jeffrey Zhang
    Sadia Ali
    April Lind
    Zachary Stoecker
    Kenneth Stauderman
    Sudarshan Hebbar
    Critical Care, 24
  • [47] Non-invasive Vagus Nerve Stimulation for COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
    Tornero, Carlos
    Pastor, Ernesto
    del Mar Garzando, Maria
    Orduna, Jorge
    Forner, Maria J.
    Bocigas, Irene
    Cedeno, David L.
    Vallejo, Ricardo
    McClure, Candace K.
    Czura, Christopher J.
    Liebler, Eric J.
    Staats, Peter
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [48] Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial
    Duijvelaar, E.
    Vanhove, A.
    Schippers, J. R.
    Smeele, P. J.
    de Man, F. S.
    Pinto, Y. M.
    Bogaard, H. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [49] Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial
    Miller, Joseph
    Bruen, Charles
    Schnaus, Michael
    Zhang, Jeffrey
    Ali, Sadia
    Lind, April
    Stoecker, Zachary
    Stauderman, Kenneth
    Hebbar, Sudarshan
    CRITICAL CARE, 2020, 24 (01)
  • [50] Effects of a 6-week at-home exercise intervention on psychological and physical indicators of well-being during the COVID-19 pandemic: Secondary analysis of a pragmatic randomized trial
    Hives, Benjamin A.
    Haight, Brook L.
    Beauchamp, Mark R.
    Liu, Yan
    Webster, Joshua
    Injege, Boaz
    Koehle, Michael S.
    Puterman, Eli
    MENTAL HEALTH AND PHYSICAL ACTIVITY, 2025, 28